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Transcellular propagation of protein aggregate “seeds” has
been proposed tomediate the progression of neurodegenerative
diseases in tauopathies and-synucleinopathies.We previously
reported that tau and -synuclein aggregates bind heparan sul-
fate proteoglycans (HSPGs) on the cell surface, promoting cel-
lular uptake and intracellular seeding. However, the specificity
and bindingmode of these protein aggregates to HSPGs remain
unknown. Here, we measured direct interaction with modified
heparins to determine the size and sulfation requirements for
tau, -synuclein, and -amyloid (A) aggregate binding to gly-
cosaminoglycans (GAGs).Varying theGAG length and sulfation
patterns, we next conducted competition studies with heparin
derivatives in cell-based assays. Tau aggregates required a pre-
cise GAG architecture with defined sulfate moieties in the N-
and 6-O-positions, whereas the binding of -synuclein and A
aggregates was less stringent. To determine the genes required
for aggregate uptake, we used CRISPR/Cas9 to individually
knock out the major genes of the HSPG synthesis pathway in
HEK293T cells. Knockouts of the extension enzymes exostosin
1 (EXT1), exostosin 2 (EXT2), and exostosin-like 3 (EXTL3), as
well as N-sulfotransferase (NDST1) or 6-O-sulfotransferase
(HS6ST2) significantly reduced tau uptake, consistent with our
biochemical findings, and knockouts of EXT1, EXT2, EXTL3, or
NDST1, but not HS6ST2 reduced -synuclein uptake. In sum-
mary, tau aggregates display specific interactions with HSPGs
that depend on GAG length and sulfate moiety position,
whereas -synuclein and A aggregates exhibit more flexible
interactions with HSPGs. These principles may inform the
development of mechanism-based therapies to block transcel-
lular propagation of amyloid protein–based pathologies.
Tau and -synuclein aggregates bind heparan sulfate pro-
teoglycans (HSPGs)3 on the cell surface, which mediate uptake
and intracellular seeding (1). However, the specificity of this
interaction is unknown. Heparan sulfate (HS) is a linear glyco-
saminoglycan (GAG) composed of disaccharide repeats of
uronic acid (iduronic or glucuronic acid) and glucosamine with
sulfate moieties at discrete N-, C2-, C3-, and C6-residues (Fig.
1) and is synthesized in all known eukaryotic cells (2, 3). Hepa-
rin is a linear GAG that is elaborated and secreted bymast cells.
It is chemically similar to HS and frequently used as a model
compound for HS. Heparin differs from HS by shorter average
chain lengths, higher contents of iduronic acid, and a higher
average number of sulfatemoieties per disaccharide unit, which
leads to higher charge density per residue (2). HS chains are
covalently attached to core proteins, forming HSPGs. Many
HSPGs are secreted into the extracellular matrix or are mem-
brane-associated either via a transmembrane domain or a gly-
cosylphosphatidylinositol anchor (2, 3). The structure of theHS
chains is determined by the activity of synthetic enzymes, avail-
ability of precursormolecules, and flux through theGolgi appa-
ratus. The structural diversity of HSPGs among different cell
and tissue types accounts for their interaction with a myriad of
proteins. The so-called heparan sulfate interactome is com-
posed of proteins involved in cell attachment, migration, inva-
sion and differentiation, morphogenesis, organogenesis, blood
coagulation, lipid metabolism, inflammation, and injury re-
sponse (2, 4). Some HS-binding proteins bind HS carbohy-
drates with great specificity. The interaction between HSPGs
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and their binding proteins can depend on modification,
domain, charge, and sugar conformation (2, 5, 6). Some inter-
actions are based on defined chemistry. For example, the bind-
ing of a protein may require spatially separated patches of sul-
fated residues on the GAGs. Purely charge-based associations
aremore flexible, as they are based on electrostatic interactions
between the positively charged residues on the binding protein
and the negatively charged sulfate residues on the HS chain (2).
We do not know whether the interactions of tau and -sy-
nuclein with HSPGs are specific to sulfation positioning or are
purely based on charge density.
We previously observed that exogenously applied tau and
-synuclein aggregates bind to HSPGs on the cell surface to
trigger cellular uptake and induce intracellular seeding (1).
Thus, the HSPG–aggregate interactionmay represent a critical
step for the spread of pathology in neurodegenerative diseases.
Other laboratories have similarly observed that A and prion
protein bind to HSPGs on the cell surface to trigger their inter-
nalization (7–11). It is not clear which HSPG properties drive
the interaction with aggregates, and if the required GAG com-
position for binding differs among amyloid proteins.
We have analyzed the GAG-binding requirements for
recombinant tau,-synuclein, andA-amyloid fibrils.We used
a small heparin mimetic library to determine the critical size
and sulfation requirements for HS to bind to aggregates in bio-
chemical and cell-based assays and CRISPR/Cas9 knockout to
test specific components of theHSPG synthesis pathway. Bind-
ing of tau fibrils to HSPGs depends on relatively specific mod-
ifications, whereas binding of -synuclein and A fibrils
seemed to be more complex and variable between different
experimental approaches.
Results
Carbohydratemicroarrays identify unique binding patterns
for amyloid proteins
Carbohydrate microarrays allow rapid analysis of interac-
tions between proteins and GAGs (12). We used this approach
to investigate the structural components of heparin that are
required for binding to tau, -synuclein, A, and huntingtin
fibrils (Fig. 2).We employed a library of modified heparin poly-
saccharides (Neoparin, Alameda, CA) to investigate sulfation
requirements for binding: heparin (Hep),N-desulfated heparin
(De-N), 6-O-desulfated heparin (De-6-O), 2-O-desulfated hep-
arin (De-2-O), O-desulfated heparin (De-O), fully desulfated
heparin (De-S, in which90% of all sulfates are removed) and
oversulfated heparin (Over-S, which contains3.5 sulfates per
disaccharide unit).
We applied nanoliter volumes of heparins at concentrations
from 0.5 to 15 M to glass microarray surfaces coated with
poly-L-lysine. We then applied biotinylated full-length tau,
-synuclein, A42, and huntingtin exon 1 (HttExon1Q50)
fibrils to the microarray, and we visualized the bound proteins
with an anti-biotin antibody taggedwithCy5. Tau,-synuclein,
and A aggregates bound heparin in a concentration-depen-
dent manner (Fig. 2). Huntingtin fibrils exhibited no binding
(data not shown) and were not analyzed further. None of the
fibrils bound desulfated heparin, suggesting that sulfation is
a critical component of the aggregate–GAG interaction (Fig.
2). Our results agreed with previous reports that tau, -sy-
nuclein, and A, but not Htt, are heparin-binding proteins
(1, 7, 13, 14).
The different seeds exhibited unique sulfation requirements
for binding. Tau efficiently bound heparin and 2-O-desulfated
heparin, whereas 6-O-desulfation,N-desulfation, orO-desulfa-
tion abolished its binding (Fig. 2). -Synuclein and A fibrils
each required O-sulfation for heparin binding. However, the
removal of N-, 6-O-, or 2-O-sulfation did not significantly
inhibit their binding, whereas desulfated heparin abolished
their binding (Fig. 2). Thus, for -synuclein and A fibrils, no
single sulfatemoiety but overall sulfationwas required tomedi-
ate binding to the GAG microarray.
Inhibition of amyloid uptake requires specific heparin
sulfation
We and others have previously observed that heparin inhib-
its the cellular binding and uptake of tau, -synuclein, and A
(1, 7). Heparin directly interacts with HS binding domains
and prevents aggregate binding to HSPGs on the cell surface.
Thus, we tested whether the structural determinants of the
aggregate–GAG interaction observed in the microarray assay
would translate to aggregate internalization and propagation in
cells.
We labeled tau,-synuclein, andA fibrils with a fluorescent
Alexa Fluor 647 dye and applied them to C17.2 cells in culture
for 4 h (tau and -synuclein) or 20 h (A), optimal times deter-
mined empirically. We measured aggregate uptake with flow
cytometry by quantifying the median fluorescence intensity
(MFI) per cell. Heparin decreased seed internalization dose-
dependently for all three fibril types (Fig. 3).
Wenext tested the desulfated heparins as inhibitors of aggre-
gate internalization (Fig. 4). Tau aggregate uptake was strongly
inhibited by 2-O-desulfated heparin, similar to standard hepa-
rin. Thus, removal of 2-O-sulfates did not disrupt tau uptake
inhibition. The inhibitory potency of 6-O-desulfated heparin
was reduced compared with 2-O-desulfated heparin and stan-
dard heparin, whereas N-desulfated heparin had virtually no
inhibitory effect (Fig. 4). In summary, as for heparin binding in
vitro, competitors for tau uptake in cells required 6-O- and
N-sulfation, whereas 2-O-sulfation was dispensable.
Figure 1. Basic disaccharide unit of heparan sulfate and heparin. The
basic disaccharide unit of heparan sulfate and heparin is composed of uronic
acid (glucuronic acid or iduronic acid, left) and glucosamine (right). Iduronic
acid results from epimerization of glucuronic acid. Heparin differs fromHS by
shorter average chain lengths, higher contents of iduronic acid, and a higher
charge density per residue. Uronic acid residues are sulfated at the 2-O-posi-
tion, whereas glucosamine residues are sulfated at the N-, 3-O-, and 6-O-
positions (2, 3).
GAG length/sulfation logic for amyloid uptake via HSPGs
J. Biol. Chem. (2018) 293(27) 10826–10840 10827
 at CA
LIFO
RN
IA
 IN
STITU
TE O
F TECH
N
O
LO
G
Y
 on July 12, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
The structural requirements differed for the inhibition of
-synuclein and A (Fig. 4). Compared with standard heparin,
removal of N-sulfation strongly reduced the inhibitory activity
of the compounds on aggregate uptake. The removal of 6-O- or
2-O-sulfation from heparin also reduced its inhibitory effect on
-synuclein and A uptake compared with unmodified hepa-
rin. Thus, N-sulfation was critical, but other sulfates also con-
tributed to aggregate binding. This result corroborated the
microarray data in that all sulfate moieties seemed to contrib-
ute to aggregate binding to GAGs. However, the relevance of
N-sulfation was different between these two experimental
approaches, with no alteration of binding by the removal of
N-sulfation in the microarray setting and a critical loss of
uptake inhibition in the uptake assay.
Inhibition of aggregate uptake requires a critical chain length
To determine the role of polysaccharide chain length, we
tested the inhibitory activity of fractionated heparins in the cell
uptake assay. Heparin fragments composed of 4, 8, 12, and 16
sugar molecules (referred to as 4-, 8-, 12-, and 16-mer, respec-
tively) were incubated with labeled aggregates, applied to C17.2
cells, and tested for inhibition of uptake (Fig. 5). For tau, shorter
heparin fragments (4- and 8-mer) had no activity, whereas the
longer fragments (12- and 16-mer) modestly inhibited uptake
Figure 2. Carbohydratemicroarray analyses identify unique amyloid–GAG interactions. Biotin-labeled tau,-synuclein, andA fibrils at 1M (monomer
equivalent) were applied to a glass surface coatedwith heparin derivatives at 0.5, 1, 5, 10, and 15M (left to right): heparin (Hep), oversulfated heparin (Over-S),
fully desulfated heparin (De-S),O-desulfated heparin (De-O), N-desulfated heparin (De-N), 2-O-desulfated heparin (De-2-O), and 6-O-desulfated heparin (De-6-
O). We applied an anti-biotin IgG antibody conjugated to Cy5 and quantified relative fibril binding by measuring fluorescence. Each protein was analyzed in
triplicate, and the data represent an average value for 10 spots at a given carbohydrate concentration. The average values were standardized to the highest
concentrationof heparin (15M) in eachdata set. Notedistinct bindingpatterns forN-desulfatedheparin, 2-O-desulfatedheparin, and6-O-desulfatedheparin.
Error bars show S.E.
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(Fig. 5). No compound had a potency similar to full-length hep-
arin (50-mer), even when taking into account the number of
individual saccharide units. We concluded that larger heparin
chains were necessary to inhibit tau uptake.
A fibrils exhibited greater sensitivity to shorter polysaccha-
rides, and 12- and 16-mer inhibited uptake. As for tau, the
uptake inhibition of A increased with the heparin chain
length. -Synuclein aggregates were also dose-dependently
inhibited by all fractionated heparins, with greater inhibitory
activity of the 12- and 16-mer compared with the shorter hepa-
rins (Fig. 5). Thus, depending on their target, heparins required
critical and distinct chain lengths to function as uptake inhibi-
tors. We concluded that tau, -synuclein, and A aggregates
each have specific structural determinants for GAG binding,
including sulfation pattern and size.
Structural requirements for inhibition of seeding
Amyloid aggregates could gain entry to cells by multiple
mechanisms, some of which could lead to seeding activity, and
others not. Thus, we tested heparins in an established seeding
assay that consists of a monoclonal “biosensor” cell line that
stably expresses tau repeat domain (RD) harboring the disease-
associated mutation P301S (Fig. S1), fused to yellow or cyan
fluorescent proteins (RD-CFP/YFP) (15, 16). Upon binding to
the cell surface, tau aggregates trigger their own internalization
and induce intracellular aggregation of RD-CFP/YFP, enabling
fluorescence resonance energy transfer (FRET). We used flow
cytometry to quantify the number of cells exhibiting FRET. An
-synuclein biosensor that expresses full-length -synuclein
with the disease-associated mutation A53T tagged to either
CFP or YFP (syn-CFP/YFP) functioned similarly (16). We did
not test for A seeding due to the lack of a functional biosensor
cell line.We incubated tau or-synuclein fibrils overnight with
heparins, prior to direct exposure of the biosensor cells and
incubation for 48 h. To improve yield (due to low seeding effi-
ciency) we re-exposed the -synuclein biosensor cell line to
aggregate–heparin complexes after passaging for an additional
48 h prior to flow cytometry. Simultaneous application of hep-
arin with tau and -synuclein fibrils to the biosensor cell lines
reduced seeding dose-dependently (Fig. 6).
We next used the desulfated heparins as competitors in the
seeding assay (Fig. 6). 2-O-Desulfated heparin blocked tau seed-
ing almost as well as heparin, whereas 6-O-desulfated heparin
lost most activity, and N-desulfated heparin lost all activity
against tau seeding. These observations were consistent with
our prior finding thatN-sulfation and 6-O-sulfation are impor-
tant for cellular tau binding and internalization, whereas 2-O-
sulfation is not. For -synuclein, N-desulfated heparin lost
most of its inhibitory activity. 6-O-Desulfated heparin and 2-O-
desulfated heparin also had reduced inhibitory activity com-
pared with standard heparin. This indicated that concordant
with results from our uptake studies,N-sulfation and to a lesser
degree 6-O-sulfation and 2-O-sulfation contributed to the inhi-
bition of -synuclein seeding.
We next tested fractionated heparins (4-, 8-, 12-, and
16-mer). We observed no appreciable inhibitory activity
against tau and only slight inhibitory activity against -sy-
nuclein with shorter heparin fragments (4- and 8-mer), and
weak activity with longer fragments (12- and 16-mer) for both
fibril types. The results were qualitatively similar to the uptake
assay, indicating that the inhibitory activity of the heparins
against seeding increased with the saccharide chain length
(Fig. 7).
HSPG synthetic genes required for uptake of aggregates
The HSPG synthesis pathway is a complex hierarchical
cascade taking place in the Golgi apparatus, involving 30
enzymes. After initial formation of a linkage region, extension
enzymes (EXT1 and EXT2) catalyze the addition of alternating
units of glucuronic acid and GlcNAc. The dual activity enzyme
N-deacetylase/N-sulfotransferase then catalyzes N-deacetyla-
tion andN-sulfation of some GlcNAc residues. Next, a variable
number of glucuronic acid residues are epimerized to iduronic
acid (2, 3). Finally, sulfate groups are attached to C3 and C6 of
glucosamine and C2 of iduronic acid and some glucuronic acid
residues (Fig. 1) (2, 3). The final structure of the HS chain in
terms of length, sugar composition, and sulfation pattern varies
substantially between different cell and tissue types. We tested
specific genes in the synthesis pathway to elucidate the struc-
tural determinants of cell-surface HSPGs and to further test
the requirement of specific sulfation patterns for aggregate
internalization.
WeusedCRISPR/Cas9 to individually knock out all the genes
in the HSPG synthesis pathway and screened for inhibition of
aggregate uptake in HEK293T cells (Table 1). We selected 5–6
separate human gRNAs for each gene and cloned them into the
lentiCRISPRv2 vector (17). Plasmids containing the gRNAs for
each genewere pooled and used for lentivirus production. Cells
were exposed to lentivirus and cultured for at least 10 days
under puromycin selection prior to phenotypic screening. As a
positive control, we included the gRNAs to target the valosin-
containing peptide (VCP) gene, because the knockout of this
gene is lethal in mammalian cells. In addition, we transduced
the available gRNAs individually to identify the functional
gRNAs for selected genes. We then used a single gRNA to pro-
duce polyclonal knockout cell lines and confirmed the presence
of indels in the predicted DNA regions by Tracking of Indels by
Decomposition (TIDE) (Fig. S3) (18). We tested several com-
Figure 3. Heparin blocks aggregate uptake of Tau, -synuclein, and A.
Tau, -synuclein, or A seeds labeled with Alexa Fluor 647 fluorescent dye
were applied to C17.2 cells with increasing doses of heparin (0.2, 2, 20, and
200 g/ml). We quantified aggregate uptake based on the MFI per cell by
flow cytometry. Heparin dose-dependently decreased cellular uptake in all
cases. Each condition was recorded in triplicate, and values represent the
average of three separate experiments. Data reflect uptake relative to the
untreated samples. Error bars show S.D.
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mercially available antibodies to verify gene knockout, but due
to the low endogenous expression levels of the genes in the
HSPG pathway (The Human Protein Atlas version 18, www.
proteinatlas.org (19, 20) and Fig. S4), we were not able to iden-
tify antibodies that reliably detected endogenous protein levels
(data not shown).
The knockout of five genes strongly inhibited tau uptake:
EXT1, EXT2, EXTL3, NDST1, and HS6ST2. Four of these five
genes (EXT1,EXT2,EXTL3, andNDST1) were also required for
-synuclein uptake (Fig. 8, Table 2, and Fig. S2). We had previ-
ously observed that EXT1 is required for cellular uptake of tau
aggregates (1). EXT1 is a glycosyltransferase that polymerizes
Figure 4. Heparin-mediated inhibition of aggregate uptake requires specific sulfation patterns.Normal heparin and 2-O-, 6-O-, andN-desulfated forms
were tested as inhibitors of cellular uptake for tau, -synuclein, and A aggregates in C17.2 cells. N- and 6-O-desulfated heparins weakly inhibited and
2-O-desulfated heparins strongly inhibited tau uptake. For -synuclein and A, removal of N-sulfation and to a lesser degree 6-O-sulfation and 2-O-sulfation
reduced inhibitor efficacy. Each condition was recorded in triplicate, and values represent the average of three separate experiments. Data reflect uptake
relative to the untreated group. Error bars show S.D.
GAG length/sulfation logic for amyloid uptake via HSPGs
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heparan sulfate chains, and knockout of the EXT1 gene reduces
HSPG expression without affecting other proteoglycan sub-
types (chondroitin and dermatan sulfate proteoglycans) (21).
EXT1 and EXT2 are co-polymerases, and both are required for
proper HS chain elongation in vivo (22). EXTL3 likewise is a
glycosyltransferase involved in the initiation and the elongation
of the HS chain, and reduced levels create longer HSwith fewer
side chains (22).
Both NDST1 and HS6ST2 knockouts substantially reduced
tau aggregate internalization (Fig. 8 and Fig. S2A). NDST1
places N-sulfate groups on glucosamine residues, whereas
HS6ST2 attaches sulfate groups to 6-O-glucosamine residues.
NDST1 is a dual activity enzyme with N-acetylase/N-sulfo-
transferase activity and is located upstream of other sulfotrans-
ferases.N-Sulfation is therefore a key regulatory step for subse-
quent modifications (3), and the knockout of this enzyme is
likely to induce changes of other sulfate moieties as well. How-
ever, in conjunctionwith our previous data that demonstrated a
loss of uptake inhibition by removal of N-sulfates and 6-O-
sulfates, we concluded that N- and 6-O-sulfate moieties are
critical for HSPG-mediated uptake of tau aggregates. On the
contrary, knockout of genes coding for 2-O- and 3-O-sulfo-
transferases had no effect (e.g. HS2ST1 and HS3ST3A1) on
tau uptake. Importantly, gRNAs targeting genes for CSPG
synthesis enzymes (CSGALNACT and CHSY1) did not affect
tau uptake (Fig. 8).
For -synuclein, only knockout of NDST1 strongly reduced
aggregate uptake (Fig. 8 and Fig. S2B). Knockout of other sul-
fotransferases mildly reduced uptake (e.g. HS2ST1), increased
uptake (e.g. HS6ST2, albeit not significantly), or had no effect
(Fig. 8). Consistent with the cell uptake and seeding data,
enzymes responsible for N-sulfation were important for -sy-
Figure 5. Inhibition of aggregate uptake requires a critical heparin size. The 4-, 8-, 12-, and 16-mer heparins were evaluated as inhibitors of tau, -sy-
nuclein, and A aggregate internalization in C17.2 cells. Potency increased with the GAG chain length. Each condition was recorded in triplicate, and values
represent the average of three separate experiments. Data reflect uptake relative to the untreated group. Error bars show S.D.
GAG length/sulfation logic for amyloid uptake via HSPGs
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nuclein uptake, whereas those responsible for sulfation at other
positions did not play a critical role. No gene knockouts
reduced the internalization of labeled transferrin, which is con-
trolled by clathrin-mediated endocytosis, indicating that our
observed effects were likely specific to macropinocytosis
(Fig. 8).
To confirm specific effects of knockout for themain genes of
interest (EXT1, NDST1, and HS6ST2), we produced knockout
cell lines in HEK293T cells and the 2 FRET biosensors by tran-
siently transfecting the gRNA/Cas9 plasmids (so that they
would eventually be lost) and culturing them for at least 10 days.
We then generated rescue plasmids with the HA-tagged cDNA
followed by internal ribosomal entry site (IRES) and an
mCherry-coding sequence. We used the cDNA plasmids to
produce lentivirus and treated the knockout cell lines for at
least 3 days to drive cDNA expression prior to uptake and seed-
ing experiments (Fig. 9).We performed aWestern blot using an
anti-HA antibody to detect plasmid overexpression (Fig. S5).
The bands for EXT1-HA (expected mass  87.7 kDa) and
NDST1-HA (expected mass  102.4 kDa) were located at the
correct locations (lanes 3 and 5, respectively, in Fig. S5). For
HS6ST2-HA (expected mass  70.2 kDa), several bands were
visible between 60 and 100 kDa, possibly due to protein
aggregation or changes of protein properties due to the HA tag.
We only detected HA tag in cells overexpressing the rescue
constructs.
Next, we used the knockout and rescue cell lines for uptake
and seeding experiments (Fig. 9). We gated for mCherry-ex-
pressing cells and quantified uptake and seeding within this
population. Knockout of all three genes was partly or fully
reversible for tau uptake and seeding when rescued with cDNA
lentivirus (Fig. 9). Similarly, knockout of EXT1 andNDST1was
partly or fully reversible for -synuclein uptake and seeding.
HS6ST2 knockout increased -synuclein uptake, similar to our
previous data (Fig. 8, albeit not significant here), and did not
change-synuclein seeding.HS6ST2 overexpression decreased
-synuclein uptake, yet paradoxically increased seeding. We
concluded that HS6ST2 modulation has complex effects on
-synuclein uptake and seeding possibly related to dysregula-
tion/compensation by multiple pathways.
In summary, targeted genetic knockout of the HSPG biosyn-
thesis pathway indicated that both tau and -synuclein inter-
nalization were mediated by HSPGs and dependent on specific
sulfotransferases. In concordance withmicroarray and heparin
competition experiments, tau uptake seemed to depend
strongly on N- and 6-sulfation via NDST1 and HS6ST2. By
contrast, -synuclein uptake depended strongly onN-sulfation
by NDST1 and to a lesser degree on 2-O-sulfation by HS2ST1.
Discussion
Using a combination of biochemical and cell-based assays,
we have investigated the HSPG structure–function relation-
ships that govern the uptake of tau, -synuclein, and A aggre-
gates. The aggregate–GAG interaction, especially for tau, is
determined by the pattern of sulfate moieties and the GAG
length. We corroborated our findings with a genetic candidate
screen of the HSPG synthesis pathway and identified specific
sulfotransferases that play a role in tau and -synuclein uptake.
Our data indicate that the interaction between HSPGs and
aggregates may be a regulated and specific biological process.
Distinct sulfation requirements for aggregate binding
Weoriginallyemployeda libraryofmodifiedheparinpolysac-
charides spotted on amicroarray to determine that the binding
of tau aggregates depended on 6-O- and N-sulfation, whereas
-synuclein andA aggregate binding depended on overall sul-
fation. We tested predictions from these studies in cell-based
uptake and seeding assays, using heparins as competitive inhib-
itors of aggregate binding to the cell surface. All data consis-
tently indicated a requirement of N- and 6-O-sulfation for tau
aggregate binding, uptake, and seeding.
In contrast, for-synuclein andA fibrils, the removal ofN-,
6-O-, or 2-O-sulfation did not significantly inhibit their binding
to the microarray, indicating that no single sulfate moiety but
overall sulfation was required to mediate binding in this exper-
imental approach. In the uptake experiments, -synuclein and
A aggregate uptake strongly required N-sulfation, whereas
2-O-sulfation and 6-O-sulfation weremoderately required.We
observed the same binding pattern for -synuclein seeding.
Thus, although N-sulfation seemed to be more relevant in the
cell-based assays, the microarray data and the cell data congru-
ently showed that all three sulfate moieties play a role for -sy-
nuclein andA internalization. Interestingly, a recent report by
Figure 6. Sulfation pattern specifies inhibition of seeding. 2-O-, 6-O-, and
N-desulfated heparins were evaluated for inhibition of tau seeding in the
P301S FRET biosensor cell line and -synuclein seeding in the A53T FRET
biosensor cell line. We used flow cytometry to quantify seeding based on the
percentage of FRET-positive cells. Inhibition of tau seeding required N-sulfa-
tion and, to a lesser extent, 6-O-sulfation. By contrast, -synuclein primarily
required N-sulfation and 6-O- and 2-O-sulfation to a lesser degree. In every
experiment, each condition was tested in triplicate. Values represent the
averageof three separate experiments for tau, and two separate experiments
for-synuclein. Thedata reflect seeding relative to the untreatedgroup. Error
bars show S.D.
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Ihse et al. (23) found that the general degree of sulfation drove
cellular -synuclein uptake rather than specific modifications
within the GAG chain. By contrast, another study demon-
strated that baculovirus uptake exhibits specificity similar to
tau, requiring N- and 6-O-sulfation, but not 2-O-sulfation, for
binding and entry into mammalian cells (24).
Zhao et al. (25) recently described a requirement of 6-O-
sulfation for tau binding to GAGs in vitro, and Rauch et al. (26)
identified a requirement for 6-O-sulfation for tau internaliza-
tion in induced pluripotent stem cell-derived neurons and
mouse brain slice culture. Differences in the observed impor-
tance ofN-sulfation could derive from individual protein prep-
arations, cell types, and assays. Given the variations in fibril
structure that can occur during formation in vitro, it is possible
that this could also play a role, as we have previously observed
distinct patterns of neuronal vulnerability to different tau
strains, which are composed of distinct fibrillar structures
(27, 28).
GAG chain length is critical
GAG chain length appears critical to mediate aggregate
binding and uptake of all amyloids studied, although we did
observe differences. Short heparin fragments (4- and 8-mer)
exhibited no inhibitory activity for tau, whereas the longer
fragments (12- and 16-mer) had only low inhibitory activity.
By contrast, A and -synuclein aggregates displayed some
degree of dose-dependent inhibition for all fractionated
heparins, with increasing inhibitory activity for longer frag-
Table 1
Genes included in the genetic screen
Major genes involved in the synthesis of HSPGswere screened for effects on tau and
-synuclein uptake. We also tested genes coding for proteoglycans core proteins
(glypicans, syndecans) and SULF1/2, which diminish HSPG sulfation via arylsulfa-
tase and endoglucosamine-6-sulfatase activities. Genes involved in the synthesis of
the chondroitin proteoglycan (CSPG) synthesis pathway, as well as SQSTM1, were
targeted as negative controls. To confirm gene knockout we targeted VCP, whose
knockout is lethal after 5 days.
Figure 7. GAG size specifies inhibition of seeding. The potency of different heparins against tau seeding in the P301S FRET biosensor cell line and
-synuclein seeding in the A53T FRET biosensor cell line depended on the chain lengths of the heparins. The 4-, 8-, 12-, and 16-mer heparins were evaluated
as inhibitors of tau and -synuclein seeding. The inhibitory potency of the heparin fragments increased with GAG chain length. In every experiment, each
condition was tested in triplicate. Values represent the average of three separate experiments for tau, and two separate experiments for -synuclein. Data
reflect seeding relative to the untreated group. Error bars show S.D.
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ments. We conclude that chain length requirements for
binding will vary among amyloid proteins, although all three
protein aggregates appear to bind longer chains with greater
avidity.
Specific sulfotransferases required for uptake
After screening all HSPG candidate genes, we observed that
knockout of only five genes (EXT1, EXT2, EXTL3,NDST1, and
HS6ST2) strongly reduced tau aggregate uptake.We had previ-
ously validated EXT1 as a modifier of tau uptake (1). EXT2,
EXTL3, NDST1, and HS6ST2 have not previously been recog-
nized to play a role in tau aggregate uptake. EXT2 and EXTL3
have similar functions to EXT1, whereas NDST1 mediates
N-deacetylation/N-sulfation, and HS6ST2 mediates 6-O-sulfa-
tion. Knockout of HS2ST1, the sole sulfotransferase for 2-O-
sulfation, did not alter tau uptake. Taken together, the genetic
data corroborate themicroarray and pharmacological data that
tau uptake is mediated by N- and 6-O-sulfation of HSPGs.
For -synuclein, the knockout of EXT1, EXT1, EXTL3, and
NDST1, but not HS6ST2, clearly reduced uptake. Knockout of
Figure 8. HSPGgenes critical for the internalizationof tau and-synuclein aggregates.Genes implicated inHSPG synthesiswere individually targeted in
HEK293T cells using CRISPR/Cas9 to create polyclonal knockout lines. The cell lines were then tested for internalization of fluorescently labeled tau and
-synuclein aggregates by measuring MFI per cell with flow cytometry. The cells were treated in parallel with fluorescently labeled transferrin to control for
nonspecific reduction of clathrin-mediated uptake. Knockout of four genes (EXT1, EXT2, EXTL3, andNDST1) reduced both tau and-synuclein uptake, whereas
the knockout ofHS6ST2 only reduced tau uptake. None of the gene knockouts reduced transferrin uptake. Datawere collected in duplicate on 2 different days
for each cell line and each aggregate type and normalized to uptake from control cells treatedwith scrambled gRNA (Sc). For transferrin uptake, the data from
all 4 experimental days was combined. Red columns indicate the gene knockouts with the strongest effects. Error bars show S.D. For statistical analyses, we
combined the averages for each experimental day. ****, p 0.0001; ***, p 0.001; **, p 0.01; one-way ANOVA, Dunnett.
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HS2ST1 mildly reduced -synuclein uptake, and knockout of
HS6ST2 slightly increased uptake and did not change -sy-
nuclein seeding. The overexpression of HS6ST2 decreased
-synuclein uptake and paradoxically increased -synuclein
seeding. Thus, the genetic data suggest that N-sulfation, and
to a lesser degree 2-O-sulfation, is important for uptake. The
genetic data partly corroborate the pharmacological data in
that N-sulfation is more relevant for -synuclein uptake and
seeding than the other moieties. However, no alteration of
binding was observed upon removal of single sulfate moi-
eties in the microarray setting. We conclude that binding
of -synuclein to HSPGs is more complex than for tau
and shows some variability between different experimental
approaches.
No other N- and/or 6-O-sulfotransferases were required for
-synuclein and tau uptake. Some of the paralogs (e.g.NDST3,
NDST4, and HS6ST3) have low or nondetectable expression
levels in HEK293 cells (The Human Protein Atlas version 18
(19, 20)). It is possible that each paralog possesses unique sub-
strate specificities and is not compensated by othermembers of
the HSPG family (e.g.NDST2 and HS6ST1). In addition, in the
mammalian brain, the HSPG composition varies substantially
between different brain areas, cell types, and developmental
stages, and little is known so far on the relevance of specific HS
sulfation patterns (29). Thus, in future studies, it will be inform-
ative to determinewhich paralogs driveN- and 6-O-sulfation in
different cell and tissue types. We also recognize that future
workmust evaluate the requirements for the genes identified in
this study in the context of post-mitotic central nervous system
neurons.
Conclusion
Our results indicate considerable specificity for tau aggregate
interaction with HSPGs. This relationship is not simply based
on charge density but on the position of sulfatemoieties as well.
Thus, further studies to investigate the structural parameters
governing aggregate uptake in vivo could be fruitful. A large
body of literature indicates that sulfated GAGs inhibit the
infectivity of the prion protein in vitro and in vivo (8, 30–32),
and our data suggest that these concepts might also be applied
to guide drug treatment for other amyloid disorders, such as
tauopathies and -synucleinopathies.
Materials andmethods
Protein preparation, fibrillization, and labeling
Recombinant full-lengthWT tau and -synuclein were puri-
fied and fibrillized as described previously (1). Huntingtin pro-
tein (Exon1 Gln-50) was prepared by solid-phase synthesis by
theKeckBiotechnologyResource Laboratory at YaleUniversity
and was labeled and fibrillized as described previously (1). Syn-
thetic A42 was purchased from Anaspec unlabeled or with a
biotin tag on the N-terminal amino acid. Biotin-A42 was
reconstituted in 1%NH4OH, lyophilized, and stored at80 °C.
Unlabeled A42 was reconstituted in 1% NH4OH, diluted in
PBS, and stored at80 °C. Fibrillization of A42 was achieved
by bringing the protein concentration to 100M (biotin-A42)
or 110 M (unlabeled A42) in 10 mM HCl and incubating for
24 h at 37 °C. -Synuclein and A42 fibrils were dialyzed into
PBS overnight using dialysis cassettes (ThermoFisher Scien-
tific). For uptake assays, fibrils were incubated with Alexa Fluor
647 succinimidyl ester dye (Invitrogen) for 1 h at room temper-
ature (molar ratios monomer/dye1:12.5 for tau and1:4 for
-synuclein and A42), quenched with 100 mM glycine for 1 h
at room temperature, and dialyzed overnight into PBS using
dialysis cassettes (ThermoFisher Scientific) to remove excess
dye. The labeled fibrils were stored at 4 °C until use.
Heparin polysaccharide suppliers
The first experiment with microarrays was performed with
heparins from Neoparin (Alameda, CA), which went out of
business upon completion of the first part of our studies. There-
fore, the heparins for the following studies were purchased
from AMSbio (Cambridge, MA). The glycochemistry of these
molecules is complicated, and the quality of the products
depends on the origin of the raw material used, the synthesis
methods, and the final purity of the preparations. We noticed
differences in inhibitory activity when performing uptake
assays with the same heparin from two different companies.
However, we still derived qualitatively similar results, e.g. that
certain defined moieties such as N-sulfation and 6-O-sulfation
are crucial for tau uptake. Also, not all the heparins used in the
microarrays were available from AMSbio, which limited the
number of heparins that could be tested in the second part of
this study.
Carbohydratemicroarrays
As described previously (12), solutions of the polysaccha-
rides (10 l per well in a 384-well plate) were spotted onto
poly-L-lysine–coated slides by using a Microgrid II arrayer
(Biorobotics; Cambridge, UK) at room temperature and 50%
humidity.We used solution concentrations between 0.5 and 15
M, and the arrayer printed 1 nl of each concentration 10 times.
The arrays were incubated in a 70% humidity chamber over-
night, followed by storage in a low-humidity, dust-free desicca-
tor. For protein binding studies, the slideswere blockedwith 3%
bovine serum albumin (BSA) in PBS (5 ml) with gentle rocking
at 37 °C for 1 h. Recombinant tau and -synuclein fibrils were
biotinylated with EZ-LinkTM Sulfo-NHS-Biotin biotinylation
kit (ThermoFisher Scientific) according to the manufacturer’s
instructions, lyophilized, and stored at80 °C until use. Biotin-
Table 2
Genes required for tau and -synuclein uptake
The knockout of the listed genes reduced aggregate uptake by 50% and was sta-
tistically significant with p  0.001 for tau and p  0.0001 for -synuclein in the
genetic candidate screen (Fig. 8); One-way Anova, Dunnett.
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A42 was purchased from Anaspec, fibrillized as described
above, lyophilized, and stored at80 °C until use. The biotiny-
lated fibrils were reconstituted in 1% BSA in PBS, and 50-l
quantities at a concentration of 1–2 M were added to the
slides, followed by incubation in a humidity chamber for 1 h.
Next, the slides were washed five times for 3min each in PBS (5
ml) while gently rocking. After thewashes, the slides were incu-
batedwith an anti-biotin IgG antibody conjugated to Cy5 in the
dark with gentle rocking for 1 h (1:5000, Molecular Probes),
washed with PBS followed by H2O, and then dried under a
gentle stream of N2. All incubations and washes were carried
out at room temperature. The microarrays were analyzed with
a GenePix 5000a scanner at 635 nm for Cy5, and fluorescence
quantification was performed using GenePix 6.0 software with
correction for local background. Each protein was analyzed in
triplicate, and the data represent an average value for 10 spots at
a given carbohydrate concentration. The average values were
standardized to the fluorescence recorded for the highest con-
Figure 9. Rescue of tau and-synuclein uptake and seeding after gene knockout.We generated knockout (KO) cell lines using HEK293T cells for uptake,
the P301S FRET biosensor cell line for tau seeding, and the A53T FRET biosensor cell line for -synuclein seeding for the main genes of interest (EXT1, NDST1,
and HS6ST2) and tested them with and without genetic rescue (R) by lentiviral cDNA. For tau, knockout of all three genes was rescued by overexpression for
bothuptake and seeding. For-synuclein, knockout of EXT1 andNDST1was rescued for uptake and seeding. However,HS6ST2 knockout increased-synuclein
uptake and did not change -synuclein seeding, whereas HS6ST2 overexpression decreased -synuclein uptake and increased seeding. Data were collected
from at least three different experiments in triplicate for tau uptake and seeding and for -synuclein uptake, and from two different experiments for -sy-
nuclein seeding. The uptake or seeding in knockout cell lines was normalized to the uptake/seeding detected in scrambled control cells (Sc). Error bars show
S.D. For statistical analyses,we combined theaverages for eachexperiment.n.s.,not significant, *,p0.05; **,p0.01; ***,p0.001; ****,p0.0001; one-way
ANOVA, Holm-Sˇída´k testing.
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centration of heparin (15M) in each data set. Statistical signif-
icance was determined using ANOVA with post hoc Tukey’s
HSD for individual comparisons; p values 0.05 were consid-
ered statistically significant. A similar experiment was per-
formed with biotinylatedmonomeric tau, -synuclein, A, and
huntingtin (data not shown), but no binding could be detected
(data not shown).
Uptake assay for heparin experiments
C17.2 cells were plated at 4000 cells per well in a 96-well
plate. Fluorescently labeled aggregates (50 nMmonomer equiv-
alent) were sonicated for 30 s at an amplitude of 65 (corre-
sponding to 80 watts; QSonica) and preincubated overnight
at 4 °C in media containing the heparins at four different
concentrations (0.2–200 g/ml). The next morning, the
aggregate–heparin complexes were applied to cells for 4 h (tau
and-synuclein) or 20 h (A) for internalization inmedia vehi-
cles of 150 l per well by media exchange. Incubation times
were optimized empirically. Cells were harvested with 0.25%
trypsin for 5 min and resuspended in flow cytometry buffer
(HBSS plus 1% FBS and 1 mM EDTA) before flow cytometry.
Cells were counted with the LSRFortessa SORP (BD Biosci-
ences). We determined the MFI per cell to quantify cellular
aggregate internalization. Each experiment was conducted
three independent times with technical triplicates per condi-
tion, and a minimum of 2000 single cells was analyzed per rep-
licate. Conditions with single cell counts below 2000 were
excluded from analysis. We determined the averageMFI of the
replicates for each condition and standardized to aggregate
uptake without inhibitor treatment within each experiment.
The standardized averages of each condition were then com-
bined for the graphs shown in this paper. Data analysis was
performed using FlowJo version 10 software (Treestar Inc.) and
GraphPad Prism version 7 for Mac OS X.
Seeding assays for heparin experiments
Tau—Wepreviously usedHEK293T cells to generate a stable
monoclonal P301S FRET biosensor cell line by overexpressing
tau RD with the disease-associated mutation P301S (Fig. S1),
and tagged at the C terminus with either CFP or YFP to detect
tau seeding (15, 16). The seeding assay was conducted as
described except that biosensor cells were plated at a density of
15,000 cells/well in a 96-well plate. Recombinant tau fibrils
were sonicated for 30 s at an amplitude of 65 (corresponding to
80 watts, QSonica) prior to use. Fibrils (100 nM monomer
equivalent) were preincubated overnight at 4 °C in media con-
taining the heparins at four different concentrations (0.2–200
g/ml). At 20–30% confluency, the seed–heparin complexes
were applied to the cells inmedia volumes of 50l per well, and
cells were incubated for an additional 48 h. We did not use
Lipofectamine to drive internalization of seeds because we
sought to monitor HSPG-mediated uptake and the inhibitory
activity of heparin blocking this process. Cells were harvested
with 0.05% trypsin and post-fixed in 2% paraformaldehyde for
10 min and then resuspended in flow cytometry buffer (HBSS
plus 1% FBS and 1 mM EDTA). The LSRFortessa SORP (BD
Biosciences) was used to perform FRET flow cytometry. We
quantified FRET as described previously (15, 16) with the fol-
lowing modification; we identified single cells that were YFP-
and CFP-positive and subsequently quantified FRET-positive
cells within this population. For each data set, three indepen-
dent experiments with three technical replicates were per-
formed. For each experiment, a minimum of 10,000 single
cells per replicate was analyzed. Wells with YFP/CFP-positive
cell counts below 5000 cells were excluded from the analysis.
Data analysis was performed using FlowJo version 10 software
(Treestar Inc.) and GraphPad Prism version 7 for Mac OS X.
-Synuclein—The monoclonal A53T FRET biosensor cell
line was previously established in our laboratory to detect -sy-
nuclein seeding, using HEK293T cells stably expressing full-
length-synuclein with the disease-associatedmutationA53T,
and tagged either with CFP or YFP (15, 16). The seeding assay
was performed similarly to the tau seeding assay, except that
biosensor cells were plated at a density of 10,000 cells/well in a
96-well plate. Recombinant -synuclein fibrils (200 nM mono-
mer equivalent) were sonicated for 30 s at an amplitude of 65
(corresponding to80 watts, QSonica) prior to use. The fibrils
were preincubated overnight at 4 °C in media containing the
heparins at four different concentrations (0.2–200 g/ml). At
20% confluency, the fibril–heparin complexes were applied to
the cells in media vehicles of 50 l per well, and cells were
incubated for 48 h. Cells were then split 1:5 into a new 96-well
plate and incubated overnight. The next day, a second treat-
ment with -synuclein fibril–heparin complexes was per-
formed as above. After an additional 48 h, cells were harvested
for flow cytometry. For the data shown, we performed two
independent experiments, with three technical replicates of
each condition in each case. Data analysis was performed as
described above for tau seeding.
Candidate screen using CRISPR/Cas9 knockout and lentiviral
transduction
5–6 human gRNA sequences per gene were selected from
theGeCKOversion 2 libraries (17). For all gRNA sequences not
beginning with guanine, a single guanine nucleotide was added
at the 5-end of the sequence to enhance U6 promoter activity.
DNA oligonucleotides were synthesized by IDT DNA and
cloned into the lentiCRISPRv2 vector (17) for lentivirus pro-
duction. The plasmids for 5–6 gRNAs for each gene were
pooled together. Lentivirus was created as described previously
(33): HEK293T cells were plated at a concentration of 1  106
cells/well in a 6-well plate. 18 h later, cells were transiently
co-transfected with PSP helper plasmid (1200 ng), VSV-G (400
ng), and gRNA plasmids (400 ng) using 7.5 l of TransIT-293
(Mirus). 72 h later, the conditioned mediumwas harvested and
centrifuged at 1000 rpm for 5 min to remove dead cells and
debris. Lentivirus was concentrated 50 using lenti-X concen-
trator (Clontech) with the concentrated pellet being resus-
pended in PBSwith 25mMHEPES (pH 7.4). For transduction, a
1:25 to 1:40 dilution of virus suspensionwas added toHEK293T
cells at a cell confluency of 20% in a 96-well plate. 20 h post-
transduction, infected cells were treated with 2g/ml puromy-
cin (Life Technologies, Inc.) and cultured for an additional 2
days, followed by passaging 1:5 and a second round of virus and
puromycin application. The cells were kept in culture for at
least 10 days after the first lentiviral transduction before using
GAG length/sulfation logic for amyloid uptake via HSPGs
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them for uptake and seeding experiments. After identification
of the genes of interest, we made knockout cell lines using the
available gRNAs individually to identify the functional gRNAs.
We identified 2–3 gRNAs per gene and used these for further
knockout experiments.
Confirmation of gene editing by TIDE (18)
We used a single functional gRNA for each gene to produce
knockout cell lines for analysis by TIDE as established by Brink-
man et al. (18) to confirm the presence of indels in predicted
DNA regions (Table S1 and Fig. S3). We extracted genomic
DNA using a protocol byMendell and co-workers (34) with the
following modifications: cell pellets from knockout cell lines
and scrambled control cells (106 cells per sample) were frozen
overnight at 80 °C, thawed the next day, and resuspended in
500 l of tissue lysis buffer (500 l of 10 STE buffer (10 mM
EDTA (pH 8.0), 100mMTris-HCl (pH 8.0), 1 MNaCl), 100l of
0.5 M EDTA, 50l of 20mg/ml proteinase K solution (Thermo-
Fisher Scientific), 200 l of 10% SDS, 4.15 ml H2O) and incu-
bated for 5 h with shaking at 550 rpm and 55 °C. Tubes were
allowed to cool down before adding 1 l of 10 mg/ml RNase A
(ThermoFisher Scientific), followed by incubation at 37 °C for
1 h while shaking at 550 rpm. Extractions were performed in
Phase Lock Gels Light (VWR) using 500 l of pH 7.9-buffered
phenol (ThermoFisher Scientific), followed by phenol/chloro-
form/isoamyl alcohol (ThermoFisher Scientific), followed by
chloroform (Sigma). Each extraction step was followed by cen-
trifugation at 16,000  g for 5 min. The upper aqueous phase
was then transferred into a new 2-ml tube, mixed with 1.3 l of
glycoblue, followed by 1 ml of 100% ethanol. The DNA was
precipitated at 80 °C for 1 h, followed by centrifugation at
15,000 g for 15 min at 4 °C. Pellets were washed with 1 ml of
75% ethanol, centrifuged again (15,000 g, 15 min, 4 °C), dried
for a fewminutes at room temperature, and solubilized in 50l
of water at room temperature for 30 min. DNA concentration
was determined with a spectrophotometer (DeNovix DS-11
FX	). PCR primers were designed according to the developer’s
instructions for TIDE (18). PCRs were performed using 100–
500 ng of genomic DNA with 2 Taq-Pro Red Complete
Polymerase (Denville Scientific, Inc.) following the manufactu-
rer’s instructions. PCR conditions were 3 min at 95 °C (1),
followed by 15 s at 95 °C, 15 s at 55 °C, and 1min at 72 °C (30)
and 10 min at 72 °C (1). The PCR product was run on a 1%
agarose gel to verify the product size and gel-extracted using the
QIAQuick gel extraction kit (Qiagen). Purified PCR samples
(12 l,4–8 ng/l) were Sanger sequenced at the sequencing
core facility at UT Southwestern Medical Center, Dallas. TIDE
analysis was performed according to the software instructions
(Table S1 and Fig. S3). The data were derived with a forward
primer for HS6ST2 and reverse primers for EXT1 and NDST1.
Because Brinkman et al. (18) found that the results of TIDE
analysis are nearly identical for both DNA strands, we did not
sequence the opposite strands.R2 represents the goodness of fit
and should be close to 0.9 for reliable data (18). R2 was slightly
lower for EXT1 and HS6ST2, but the aberrant sequence signal
was clearly visible in each graph (Fig. S3).
Uptake assay for knockout screen
The uptake assay for the knockout screen was conducted as
described above with the following modifications. Knockout
cell lines were plated at 20,000 cells per well in a 96-well plate.
The next day, aggregates labeled with Alexa Fluor 647 were
sonicated for 30 s at an amplitude of 65 (corresponding to80
watt, QSonica),mixedwith transferrin labeledwithAlexa Fluor
488 (Life Technologies, Inc.), and applied to the cells in a vehi-
cle of 50 l of media for 4 h. Final concentrations of tau and
-synuclein in the media were 25 nM (monomer equivalent)
and of transferrin 25 g/ml. Cells were harvested with 0.25%
trypsin for 5 min and resuspended in flow cytometry buffer
(HBSS plus 1% FBS and 1 mM EDTA) before flow cytometry.
Cells were counted with the LSRFortessa SORP (BD Biosci-
ences). Data were collected from the same cell lines in duplicate
on two different days. For each replicate, 10,000 single cells
were analyzed. Uptake was normalized to the uptake detected
in scrambled control cells. For the analysis, we combined the
averages for each experimental day to determine the multi-
plicity adjusted p values using one-way ANOVA and Dun-
nett testing. Data analysis was performed using FlowJo ver-
sion 10 software (Treestar Inc.) and GraphPad Prism version
7 for Mac OS X.
Making knockout cell lines for rescue experiments
Two to three functional gRNA plasmids identified as de-
scribed above were pooled and used for transfection. 30,000
HEK293T cells or FRET biosensors cells (for tau and -sy-
nuclein seeding) were plated per well in a 96-well plate. The
next day, 100 ng of DNAwas combinedwithOptiMEM (Gibco,
Life Technologies, Inc.) to a final volume of 10 l per well.
Similarly, 0.5 l of Lipofectamine-2000 per well (Invitrogen,
Life Technologies, Inc.) was combined with OptiMEM (Gibco,
Life Technologies, Inc.) to a final volume of 10 l per well in a
master mix solution. Both solutions were mixed after 5 min of
incubation and incubated for an additional 20 min at room
temperature, followed by dropwise addition to the cells at about
70% of cell confluency. We applied puromycin once at 2 g/ml
24 h after transfection. Cells were cultured to confluency, pas-
saged, and transfected in a similar way two more times. Cells
were maintained in culture at least 10 days after the last trans-
fection and prior to uptake and seeding experiments.
Cloning for rescue experiments
We used our previously described lentiviral FM5-YFP plas-
mid (27), replaced the human ubiquitin C promoter with a
human CMV promoter, replaced the YFP sequence with an
HA-tag coding sequence, and added an IRES element followed
by an mCherry-coding sequence downstream of the insert.
The resulting FM5/HA IRES mCherry vector bicistronically
expresses an HA-tagged insert and mCherry protein from the
same promoter. For the rescue experiments, EXT1 (pCMV3-
Ext1-HA; Sino Biological), NDST1 (pUC75-NDST1; Gen-
script), andHS6ST2 (pANT7-cGST-HS6ST2; DNASUPlasmid
Depository, Arizona State University (35)) cDNA was sub-
cloned into the FM5/HA IRES mCherry vector using Gibson
assembly Master Mix (New England Biolabs) according to the
GAG length/sulfation logic for amyloid uptake via HSPGs
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manufacturer’s instructions. All genes were sequenced before
use.
Rescue experiments
We used the cDNA IRES mCherry constructs to produce
lentivirus and concentrated it 50 as described above. We
applied the lentivirus at a 1:600 dilution to the knockout cell
lines for 3 days prior to uptake and seeding experiments. We
also used higher and lower lentivirus concentrations (dilutions
between 1:160 and 1:2400), which led to toxicity for higher con-
centrations and reduced the percentage of mCherry-positive
cells at lower concentrations, without significantly improving
the rescue effects. We performed uptake and seeding experi-
ments as described, with the following modifications. For
uptake experiments, cells were treated with 100 nM (monomer
equivalent) Alexa Fluor 647-labeled recombinant fibrils (tau or
-synuclein). For tau seeding experiments, cells were treated
2 h after plating at a final concentration of 100 nM (monomer
equivalent) recombinant tau fibrils for 72 h. For -synuclein
seeding experiments, -synuclein fibrils were sonicated for a
total of 30 min (alternating 30 s on and 90 s off to avoid heating
of the water bath) at an amplitude of 50 (QSonica) prior to use.
Freshly sonicated -synuclein fibrils were applied to the cells
2 h after plating at a final concentration of 800 nM and incu-
bated for 72 h. Flow cytometry data were collected from the
same cell lines in triplicate on at least 2 different days. For data
acquisition and analysis, we gated formCherry-expressing cells
and quantified uptake and seeding within this cell population.
The quantification of uptake (median fluorescence intensity of
Alexa Fluor 647) and seeding (percentage of FRET positive
cells) was then performed as described above. For each repli-
cate,5000 single cells for uptake experiments and 10,000 cells
for seeding experiments were analyzed. Uptake and seeding
were normalized to the uptake/seeding detected in control cells
treated with scrambled gRNA. For the analysis, we combined
the averages for each experimental day to determine the multi-
plicity adjusted p values using one-way ANOVA and Holm-
Sˇída´k testing. Data analysis was performed using FlowJo ver-
sion 10 software (Treestar Inc.) and GraphPad Prism version 7
for Mac OS X.
Western blotting to confirm overexpression of rescue plasmids
TheHEK293T knockout cell lines and the scrambled control
cell linewere grown to confluency in a 6-well cell culture dish (1
well per cell line). Cells were pelleted at 1000 rpm, washed with
PBS, and frozen at 80 °C. Pellets were thawed on ice, resus-
pended in 100 l of lysate buffer (0.05% Triton X-100, protease
inhibitor, PBS), incubated for 10min at 4 °C while rotating, and
centrifuged for 5 min at 1000  g. The supernatant was pre-
served and quantified for total protein content by the Bradford
assay. Samples were boiled for 5 min with SDS-PAGE sample
buffer, and 10 g of total protein were loaded into a 4–12%
polyacrylamide gel (NuPAGE). Using electrophoresis, samples
were run for 60 min and transferred to a PVDF membrane
(semi-wet transfer method). After blocking in 5% nonfat dry
milk, membranes were incubated with primary antibody
(1:4000 anti-HA tag antibody-ChIP Grade (ab9110, Abcam)) at
room temperature for 2 h. Following an incubation for 2 h at
room temperature with secondary antibody (1:4000; anti-Rb
HRP-labeled; Jackson Immunotherapy), membranes were
imaged by the ECL Prime Western blotting detection system
(ThermoFisher Scientific) using a digital imager (Syngene).
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